Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Lifeward Ltd. incurred loan of initial principal amount of $525,000 with Oramed Pharmaceuticals, Inc. at 24% per annum maturing the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval.
- Instrument
- loan
- Principal
- initial principal amount of $525,000
- Counterparty
- Oramed Pharmaceuticals, Inc.
- Rate
- 24% per annum
- Maturity
- the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval
- Event
- incurrence
Exact text from the filing
On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lifeward Ltd. entered into Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. valued at initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 (effective 2026-02-12).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Oramed Pharmaceuticals, Inc.
- Value
- initial principal amount of $525,000, which amount may be increased by up to an additional $975,000
- Effective
- 2026-02-12
Exact text from the filing
On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 upon the mutual consent of the parties.
View on SEC.gov